Home » Stocks » PHIO

Phio Pharmaceuticals Corp. (PHIO)

Stock Price: $2.29 USD -0.03 (-1.29%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $2.25 -0.04 (-1.75%) Apr 16, 7:00 PM
Market Cap 30.72M
Revenue (ttm) n/a
Net Income (ttm) -8.79M
Shares Out 4.59M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE 1.10
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $2.29
Previous Close $2.32
Change ($) -0.03
Change (%) -1.29%
Day's Open 2.32
Day's Range 2.20 - 2.32
Day's Volume 380,439
52-Week Range 1.65 - 6.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Phio Pharmaceuticals Corp (NASDAQ: PHIO) announced new preclinical data for the Intasyl platform in tumor settings. These data were presented today during the AACR Annual Meeting 2021.

5 days ago - Benzinga

MARLBOROUGH, Mass., April 10, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...

1 week ago - PRNewsWire

MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...

3 weeks ago - PRNewsWire

MARLBOROUGH, Mass., March 11, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...

1 month ago - PRNewsWire

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has entered into a clinical development collaboration with AgonOx Inc to develop novel T cell-based cancer immunotherapies. The collaboration will use Phio's lea...

1 month ago - Benzinga

MARLBOROUGH, Mass., Feb. 23, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

1 month ago - PRNewsWire

MARLBOROUGH, Mass., Feb. 17, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

2 months ago - PRNewsWire

MARLBOROUGH, Mass., Jan. 25, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

2 months ago - PRNewsWire

MARLBOROUGH, Mass., Jan. 21, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

2 months ago - PRNewsWire

MARLBOROUGH, Mass., Jan. 4, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...

3 months ago - PRNewsWire

MARLBOROUGH, Mass., Nov. 19, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

4 months ago - PRNewsWire

MARLBOROUGH, Mass., Nov. 10, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

5 months ago - PRNewsWire

MARLBOROUGH, Mass., Nov. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...

5 months ago - PRNewsWire

MARLBOROUGH, Mass., Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

5 months ago - PRNewsWire

MARLBOROUGH, Mass., Sept. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp.

7 months ago - PRNewsWire

MARLBOROUGH, Mass., Aug. 12, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp.

8 months ago - PRNewsWire

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares more than doubled on Friday after the firm announced positive data from its cancer study at the American Society of Clinical Oncology (ASCO) 2020 Virtual...

10 months ago - 24/7 Wall Street

MARLBOROUGH, Mass., May 14, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...

11 months ago - PRNewsWire

About PHIO

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which... [Read more...]

Industry
Biotechnology
CEO
Gerrit Dispersyn
Employees
10
Stock Exchange
NASDAQ
Ticker Symbol
PHIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for PHIO stock is "Buy" and the 12-month stock price forecast is 4.00.

Price Target
$4.00
Analyst Consensus: Buy